Summary of the 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Prepared by the Czech Society of Cardiology
2017
Abstract
CVDcardiovascular disease HER2human epidermal growth factor receptor 2 HFheart failure T-DM1trastuzumab, pertuzumab, trastuzumab-emtansine TKIlapatinib LVleft ventricular ACEangiotensin-converting enzyme (ACE) inhibitors VEGFvascular endothelial growth factor LVEFleft ventricular ejection fraction MImyocardial infarction ECGelectrocardiography CTRCDcancer therapeutics-related cardiac dysfunction CMRcardiovascular magnetic resonance CADcoronary artery disease ARBangiotensin II receptor blockers VTEvenous thromboembolism LMWHlow molecular weight heparin VKAvitamin K antagonist INRinternational normalized ratio NOACnon-VKA oral anticoagulant VHDvalvular heart disease PADperipheral artery disease BNPB-type natriuretic peptide